Zobrazeno 1 - 10
of 12
pro vyhledávání: ''
Autor:
Alexander Melamed, Melissa Beauchemin, Melissa K. Accordino, Jason D. Wright, Dawn L. Hershman, Jacob C Cogan, Rohit R. Raghunathan
Publikováno v:
Cancer Research. 81:GS3-08
Introduction Cancer surgery has been linked to chronic opioid use post-operatively, with up to 10% of patients continuing to fill opioid prescriptions beyond 3 months after surgery. However, previous studies have not compared post-operative opioid us
Autor:
Yu-Ming Shen, Dejan Juric, Murat Akdere, Aleix Prat, Hope S. Rugo, Stephen Chia, Christina Arce, Florence Lerebours, Nicholas C. Turner, Eva Ciruelos, Pamela Drullinsky, Rafael Villanueva Vazquez
Publikováno v:
Cancer Research. 81:PD2-07
Introduction: Mutations in PIK3CA, which encodes the α-isoform of phosphatidylinositol 3-kinase (PI3Kα), occur in ~40% of patients (pts) with HR+, HER2- ABC and can contribute to endocrine resistance. Alpelisib (ALP), a PI3Kα-selective inhibitor a
Publikováno v:
Mol Cancer Ther
Despite frequent overexpression of numerous growth factor receptors by pancreatic ductal adenocarcinomas (PDAC), such as EGFR, therapeutic antibodies have not proven effective. Desmoplasia, hypovascularity, and hypoperfusion create a functional drug
Autor:
Roberto A. Leon-Ferre, W Mitchell, J Le-Rademacher, P Novotni, Charles L. Loprinzi, R Glaser, Copur, S Terstriep, S Page, C Jones, Stephen N. Birrell, Armando E. Giuliano
Publikováno v:
Cancer Research. 79:P4-16
Background: Aromatase inhibitors are a mainstay hormone receptor-positive breast cancer treatment. AIA occur in up to 50% of patients (pts), adversely affecting quality of life and treatment compliance. A small phase II clinical trial of oral testost
Autor:
Analia Azaro, L de la Pena, Meritxell Bellet, Gini F. Fleming, E.M. Ciruelos, Meredith M. Regan, Gustavo Catalan, A. Lluch, Antonio González-Martín, Uriel Bohn, István Láng, Khalil Zaman, Roser Ferrer, Agnita Rajasekaran, M Ángel Climent, Antoni Avella, Kathryn P. Gray, PA Francis
Publikováno v:
Cancer Research. 79:P4-14
Background: Optimal endocrine therapy for premenopausal pts with early HR+ BC may depend on complete estrogen suppression with GnRH analog, which is crucial when using concurrent aromatase inhibitors (AIs). SOFT-EST is a prospective substudy of the p
Autor:
Karin Jordan, Lee S. Schwartzberg, Sujata Arora, Bernardo Leon Rapoport, Dan Powers, Rudolph M. Navari
Publikováno v:
Cancer Research. 77:P5-11
Background: Patients (pts) with breast cancer often receive highly emetogenic chemotherapy, such as anthracycline plus cyclophosphamide (AC). Additionally, young age and female gender are risk factors for chemotherapy-induced nausea and vomiting (CIN
Publikováno v:
Cancer Research. 76:P1-10
Background: Patients (pts) with breast cancer (BC) are at high risk for developing chemotherapy-induced nausea and vomiting (CINV) due to the emetogenicity of chemotherapy (often AC-based) and predisposing risk factors including young age and female
Autor:
Michael B. Sporn, Charlotte R. Williams, Martine Cao, Renee Risingsong, Karen T. Liby, Darlene B. Royce
Publikováno v:
Cancer Prevention Research. 9:105-114
LG101506 was originally synthesized to overcome some of the undesirable side effects of rexinoids. We compared the anticarcinogenic action of LG101506 and LG100268 and for the first time showed that both drugs are useful for prevention of lung cancer
Autor:
Brad S. Kahl, Amy Rock, Michelle Becker-Hapak, Julia A. Wagner, Liza Hernandez, Peter R. Rhode, Kyle Conradi, Feng Gao, Todd A. Fehniger, Ethan McClain, Emily K. Jeng, Neha Mehta-Shah, Nancy L. Bartlett, Veronika Bachanova, Melissa M. Berrien-Elliott, Amanda F. Cashen, Jack O. Egan, Hing C. Wong, Brian T. Hess
Publikováno v:
Cancer Research. 78:CT146-CT146
Immunotherapy is an effective modality for cancer treatment. IL-15 is a cytokine that stimulates CD8+ T cell and NK cell survival, metabolism, and anti-tumor immunity. We hypothesized that IL-15 therapy will augment anti-cancer immune responses in co
Autor:
Frank Halley, Mikhail Levit, Laurent Debussche, Patrick Cohen, Dietmar Hoffman, Vicky Richon, Sylvie Vincent, Gary McCort, Monsif Bouaboula, Karl Hsu, Zhuyan Guo, Carlos Garcia-Echeverria, Fangxian Sun, Maysoun Shomali, Laurent Schio, Francisco Adrian, Hong Cheng, Chris Soria, Laurent Bestret, Natalia Malkova, Christoph Winter, Malvika Koundinya, Joanne Lager, Stephane Poirier, Hui Cao, Youssef El-Ahmad, Jane Cheng
Publikováno v:
Cancer Research. 78:943-943
Despite resistance to endocrine therapies, estrogen receptor-positive (ER+) breast cancers (BC) still rely on ER. Eliminating ER by inducing its degradation with selective ER downregulators (SERD) should induce complete ablation of ER pathways. The c